The Deal in Detail
According to Zymeworks, Roche gains global rights to develop and commercialise ZW209. The financial structure of the agreement includes:
- An upfront payment of $55 million.
- A further $40 million when Roche begins a planned dose-optimisation study.
- Up to $718 million in development, regulatory and commercial milestone payments, plus tiered royalties on sales.
Roche will take over development of the drug after Zymeworks completes the dose-escalation portion of an ongoing early-stage study. According to Zymeworks CEO Kenneth Galbraith, the first patient is expected to be enrolled before the end of 2026.
Targeting DLL3 – the Cancer Cell’s “Address”
ZW209 targets DLL3, a protein commonly found on the surface of small-cell lung cancer cells but rarely seen in healthy tissue. That makes DLL3 an ideal target: a drug can attack the tumour while causing less harm to other organs.

















